Ignite Creation Date:
2025-12-25 @ 1:01 AM
Ignite Modification Date:
2025-12-27 @ 1:32 PM
Study NCT ID:
NCT06463093
Status:
RECRUITING
Last Update Posted:
2025-02-03
First Post:
2023-11-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin
Sponsor:
Central Hospital, Nancy, France
Organization:
Study Overview
Official Title:
Contribution of Brain Positon Emission Tomography With 18 Flurodeoxyglucose Labelled With Fluorine 18 for the Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin
Status:
RECRUITING
Status Verified Date:
2025-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATEPDIPSY
Brief Summary:
The aim of the research is to analyze whether 18F-FDG PET helps in the diagnosis and therefore in the management of the patient.
Detailed Description:
Neurocognitive disorder or Mild Cognitive Impairment corresponds to a decline in one or more cognitive functions; compared to the previous level of performance.
Indeed, the prevalence of neurodegenerative pathologies is estimated at more than one million according to Santé Publique France, due to the aging of the population. To be compared with the prevalence of the population suffering from a psychiatric disorder estimated at one in five people, or 13 million French people, in 2021.
With the increase in the prevalence of these two entities and their clinical entanglement, the question arises of the origin of neurocognitive disorders, is it a manifestation of a psychiatric pathology or a neurodegenerative pathology not yet diagnosed.
If this is the case, the patient's prognosis is modified with a pejorative evolution and a loss of autonomy which is to be anticipated. This delay deprives the patient and his family of interventions likely to alleviate behavioral disorders; maintain a level of autonomy compatible with life at home; alleviates the burden and improves the quality of life of caregivers.
Indeed, the prevalence of neurodegenerative pathologies is estimated at more than one million according to Santé Publique France, due to the aging of the population. To be compared with the prevalence of the population suffering from a psychiatric disorder estimated at one in five people, or 13 million French people, in 2021.
With the increase in the prevalence of these two entities and their clinical entanglement, the question arises of the origin of neurocognitive disorders, is it a manifestation of a psychiatric pathology or a neurodegenerative pathology not yet diagnosed.
If this is the case, the patient's prognosis is modified with a pejorative evolution and a loss of autonomy which is to be anticipated. This delay deprives the patient and his family of interventions likely to alleviate behavioral disorders; maintain a level of autonomy compatible with life at home; alleviates the burden and improves the quality of life of caregivers.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: